HK Stock Market Move | ASCLETIS-B(01672) increased by over 7%, institutions point to the company's catalyst-rich focus on weight reduction and blood sugar reduction this year.

ASCLETIS-B (01672) rose more than 7%, up 7.42% as of press time, to 6.37 Hong Kong dollars, with a turnover of 13.22 million Hong Kong dollars. On the news side, Guli Pharmaceutical recently announced that the randomized, double-blind, placebo-controlled Phase Ib multiple dose escalation (MAD) study of a once-daily oral tablet for the treatment of obese patients (body mass index (BMI) of 30-40 kg/m2) conducted in the United States has achieved positive interim results in the first two cohorts. Haitong pointed out that the company has a rich catalyst readout for weight loss & diabetes area by 2025, and is optimistic about the global competitiveness of its pipeline ASC30 and ASC47, recommending attention to the company's progress. The company's clinical stage pipeline in the weight loss & glycemic control area currently includes ASC30, an oral and subcutaneous injection form of small molecule GLP1R agonist, as well as ASC47, a fat-targeting small molecule THR injection.